Novo Nordisk announced on December 14th local time that all regulatory closing conditions related to the review of Novo Nordisk's acquisition of US contract pharmaceutical company Catalent have been met, and both parties are now free to complete the transaction. Novo Nordisk expects the acquisition to be completed in the coming days.